Rosetta Genomics diagnostic news

Rosetta will restructure and reduce headcount by 14 (20%) to 58 to reduce expenses. These cuts will come primarily in R&D and general and administrative positions. These reductions, which are effective in December, will reduce annual operating expenses by about $4 million and reduce the company's monthly cash burn rate by 32%. Rosetta said the reductions would give it sufficient cash to fund operations through March 2011.

Rosetta said the changes would not affect its planned launches of its second-generation miRview diagnostics, including its miRview mets to identify the tissue of origin in metastatic tumors. The microRNA-based diagnostic is expected to launch by year end outside the U.S. ...